Zambon Biotech, a biotech company part of the Zambon group, has announced that the first patient with advanced Parkinson's disease has been enrolled in the European Phase 3b ADIP study. This study is testing a drug called IPX203, which is designed to treat Parkinson's disease. The goal of the study is to compare the effectiveness and safety of IPX203 with standard immediate-release levodopa/carbidopa (LD/CD) treatment.
IPX203 is a new version of the standard Parkinson's medication, made to work faster and last longer than regular LD/CD. It combines both fast-acting and extended-release ingredients to provide more consistent treatment throughout the day. Zambon Biotech has already partnered with Amneal Pharmaceuticals to bring IPX203 to the European Union, UK, and Switzerland, and it submitted the drug for approval in June 2025.
The ADIP study will focus on improving "ON time" (when symptoms are under control) and reducing "OFF time" (when symptoms return). The trial is different from earlier studies because it allows for flexible dosing schedules, based on each patient’s needs. The study will last up to 25 weeks, including a 12-week treatment period, and will involve 92 patients from sites in Italy, Spain, and Poland.
According to Coherent Market Insights, Parkinsons Disease Therapeutics Market is estimated to be valued at USD 5.85 Bn in 2025 and is expected to reach USD 9.39 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.0% from 2025 to 2032.
“Dosing the first person in our phase 3b ADIP study marks an important milestone for our company and for the people living with Parkinson’s disease who urgently need new therapies that truly improve their quality of life and the therapeutic outcomes” explained Mathias Knecht, M.D., Chief Medical Officer, Zambon Biotech. “We recognize the substantial need for new treatment options, and with ADIP we aim to demonstrate the potential of IPX203 to become a core therapy for people with PD and moderate to severe motor fluctuations”.
“At Zambon Biotech we are fully committed to build a long-term pipeline of innovative medicines that make patients’ lives better. Given our group’s capabilities in commercialization and our existing footprint in neurology, particularly Parkinson’s, we believe IPX203 could represent a valuable therapeutic option in Europe to improve the lives of moderate to severe Parkinson patients” said Frank Weber, M.D, Chief Executive Officer at Zambon Biotech.
Source:
News Room: Zambon Biotech
Company: Zambon Biotech
